



Medicine Supply Notification

MSN/2024/093

Naloxone (Nyxoid[®]) 1.8mg/0.1ml nasal spray unit dose

Tier 2 – medium impact*

Date of issue: 28/08/2024

Link: [Medicines Supply Tool](#)

Summary

- Naloxone (Nyxoid[®]) 1.8mg/0.1ml nasal spray unit dose is out of stock until w/c 30th September 2024.
- Naloxone 1.26mg/0.1ml nasal spray unit dose remains available and can support a full increase in demand.
- Naloxone (Prenoxad[®]) 1mg/ml solution for injection pre-filled syringes remain available and can support a full increase in demand.

Actions Required

All community drug and alcohol services, HM Prisons, Trusts and services who prescribe, supply and/or administer naloxone should note the following:

- Naloxone 1.26mg/0.1ml nasal spray unit dose should be ordered in accordance with requirements and not over ordered, to maintain availability of supply;
- Utilise naloxone 1.26mg/0.1ml nasal spray unit dose, taking into account usage in children is off-label, and ensuring the patient is not intolerant to any excipients (see Supporting Information);
- Where naloxone nasal spray is unavailable, utilise Prenoxad[®] (naloxone) 1mg/ml solution for injection pre-filled syringe;
- Patients supplied naloxone nasal spray or pre-filled syringe to take home must be provided appropriate training on how to use and administer these products; and
- Organisations should ensure any local policies, Standard Operating Procedures and Patient Group Directions give sufficient flexibility to allow available products to be used.

Supporting information

Clinical Information

Both Nyxoid[®] 1.8mg/0.1ml and naloxone 1.26mg/0.1ml nasal sprays are intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid[®] is licensed for use in adults and adolescents aged 14 years and over. Naloxone 1.26 mg nasal spray is licensed for use in adults and contains the preservative benzalkonium chloride, which can cause irritation.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Prenoxad injection is also intended for emergency use in the home or other non- medical setting by appropriate individuals or in a health facility setting for the complete or partial reversal of respiratory depression induced by natural and synthetic opioids. It is licensed for use in adults. It is not intended to be used for children in the home setting other than by an appropriately trained healthcare professional.

Patient Safety

Prenoxad® (Naloxone) 1mg/1ml solution for injection pre-filled syringes are the only naloxone injectable product that should be supplied to patients to take home as the pack contains needles. Generic naloxone 1mg/ml solution for injection pre-filled syringes are for hospital use and *do not* contain needles.

Links to further information

[SmPC – Nyxoid 1.8 mg/0.1ml nasal spray, solution in a single-dose container](#)

[SmPC- Naloxone 1.26 mg/0.1ml nasal spray unit dose](#)

[SmPC – Prenoxad 1mg/ml Solution for Injection in a pre-filled syringe](#)

[BNF – Naloxone](#)

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Specialist Pharmacy Service Regional Pharmacy Procurement Team, who will escalate to national teams if required.

REGION	Lead RPPS	Email	Associate RPPS	Email
Midlands	Andi Swain	andi.swain@nhs.net	vacant	
East of England	James Kent	james.kent@nhs.net	Tracy McMillan	tracy.mcmillan2@nhs.net
London	Jackie Eastwood	jacqueline.eastwood@gstt.nhs.uk	Daniel Johnson	Daniel.Johnson@gstt.nhs.uk
North East and Yorkshire	David Allwood	davidallwood@nhs.net	Penny Daynes	penny.daynes@nhs.net
North West	Richard Bateman	richard.bateman@liverpoolft.nhs.uk	Andy Stewart	Andrew.stewart@liverpoolft.nhs.uk
South East	Alison Ashman	Alison.Ashman@berkshire.nhs.uk	Melanie Renney	melanie.renney@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk	Natalie Bryson	Natalie.Bryson@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2024/093.

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.